Get the Stockscreener App
2.38
4.39%
0.10
After Hours:
2.40
0.02
+0.84%
Compugen Ltd stock is traded at $2.38, with a volume of 103.54K.
It is up +4.39% in the last 24 hours and up +13.88% over the past month.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.
See More
Previous Close:
$2.28
Open:
$2.34
24h Volume:
103.54K
Relative Volume:
0.24
Market Cap:
$225.11M
Revenue:
$72.66M
Net Income/Loss:
$34.86M
P/E Ratio:
6.5027
EPS:
0.366
Net Cash Flow:
$-62.91M
1W Performance:
+1.71%
1M Performance:
+13.88%
6M Performance:
+17.82%
1Y Performance:
+55.56%
1-Day Range:
$2.284
$2.385
1-Week Range:
$2.26
$2.52
52-Week Range:
$1.295
$3.235
Compugen Ltd Stock (CGEN) Company Profile
Compare CGEN vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CGEN
Compugen Ltd
|
2.38 | 215.65M | 72.66M | 34.86M | -62.91M | 0.366 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Compugen Ltd Stock (CGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-07-26 | Initiated | Lake Street | Buy |
| Jan-07-26 | Initiated | H.C. Wainwright | Buy |
| Jan-13-25 | Initiated | Oppenheimer | Outperform |
| Aug-05-22 | Downgrade | Jefferies | Buy → Hold |
| May-26-20 | Resumed | JMP Securities | Mkt Outperform |
| May-13-20 | Initiated | Stifel | Buy |
| May-07-20 | Initiated | SVB Leerink | Outperform |
| Apr-22-20 | Initiated | ROTH Capital | Buy |
| Mar-24-20 | Initiated | SunTrust | Buy |
| Jan-16-20 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-29-18 | Initiated | Oppenheimer | Outperform |
| Feb-01-16 | Resumed | Oppenheimer | Outperform |
| Oct-15-15 | Initiated | FBR Capital | Outperform |
| Apr-23-15 | Resumed | Jefferies | Buy |
| Apr-21-15 | Initiated | Oppenheimer | Outperform |
| Feb-07-14 | Initiated | MLV & Co | Buy |
| Dec-28-09 | Reiterated | Cantor Fitzgerald | Buy |
| Jul-29-09 | Initiated | Cantor Fitzgerald | Buy |
View All
Compugen Ltd Stock (CGEN) Latest News
Compugen Ltd (CGEN) Income Statement - TradingKey
CGEN|Compugen Ltd|Price:2.365|Chg%:+0.085 - TradingKey
Compugen Ltd (CGEN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Compugen Ltd (CGEN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CGEN|Compugen Ltd|Price:2.375|Chg%:+0.095 - TradingKey
Compugen Ltd (CGEN) Cash Flow - TradingKey
TradingKey - TradingKey
CGEN|Compugen Ltd|Price:2.280|Chg%:-0.060 - TradingKey
Evogene Ltd. (EVGN) stock price, news, quote and history - Yahoo Finance UK
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Lake Street Maintains Compugen(CGEN.US) With Buy Rating, Raises Target Price to $6 - Moomoo
Compugen to Participate in BTIG Biotechnology Conference 2026 - marketscreener.com
Compugen (CGEN) to Release Q2 Financial Results on August 3, 202 - GuruFocus
Compugen's Cancer Immunotherapy Update Is Set for Aug. 3 - Stock Titan
Compugen to release Q2 2026 results, host conference call - Bitget
Compugen (CGEN) SVP Levine exercises options and sells 1,875 shares under plan - Stock Titan
CGEN Stock Update: Virtual Meeting Announcement - GuruFocus
Compugen Ltd. (CGEN) Surges 3.5% Amid Biotech Sector Renewed InterestBollinger Expansion - dars.gov.et
Compugen Q1 2026 Earnings: EPS Misses Estimates, No Revenue ReportedEarnings Power Value - dars.gov.et
Compugen (CGEN) Edges Lower as Shares Test Support Near $2.03Gamma Squeeze - dars.gov.et
CGEN Q1 2026 Earnings: Narrowing Net Loss and Pipeline Progress Fuel OptimismGuidance Revision Trend - dars.gov.et
Compugen Ltd (CGEN) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Compugen Ltd (CGEN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Enterprise value to EBITDA forward of Compugen Ltd. – NASDAQ:CGEN - TradingView
Enterprise value to revenue forward of Compugen Ltd. – NASDAQ:CGEN - TradingView
Enterprise value to EBIT forward of Compugen Ltd. – NASDAQ:CGEN - TradingView
Price to sales forward of Compugen Ltd. – NASDAQ:CGEN - TradingView
Compugen Ltd. Actuals & Estimates (NASDAQ:CGEN) - TradingView
Compugen Ltd (CGEN) Institutional Confidence - TradingKey
Compugen Ltd. Actuals & Estimates (TASE:CGEN) - TradingView
CGEN Forecast — Price Target — Prediction for 2027 - TradingView
Lake Street Maintains Compugen(CGEN.US) With Buy Rating, Cuts Target Price to $5 - Moomoo
Compugen presents ovarian cancer trial poster at ESMO meeting - Investing.com UK
Compugen presents ovarian cancer trial poster at ESMO meeting By Investing.com - Investing.com South Africa
Compugen spotlights COM701 ovarian trial at ESMO congress - Stock Titan
Compugen presents trial data on COM701 for ovar... - Pluang
Compugen (CGEN) Stock Faces Mixed Analyst Target Changes After Cautious Valuation Revisions - Yahoo Finance UK
Compugen Ltd (CGEN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Compugen Ltd (CGEN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Compugen Ltd (CGEN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Compugen Ltd (CGEN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Compugen Ltd (CGEN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
CGEN Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Stage Continues; Stock DeclinesStrong Earnings Momentum - newsline.com
CGEN Q1 2026 Earnings: EPS Misses Estimates amid R&D FocusRevenue Beat Analysis - newsline.com
Compugen Ltd. (CGEN) Q1 2026 Earnings: EPS Misses Estimates as Clinical-Stage Biotech Continues DevelopmentBuyback Announcement Report - dars.gov.et
Compugen Ltd (CGEN) to Present MAIA-Ovarian Trial Progress at Eu - GuruFocus
COMPUGEN ($CGEN) Releases Q4 2025 Earnings - Quiver Quantitative
Compugen to present ovarian cancer trial poster at ESMO - Investing.com UK
Compugen to present ovarian cancer trial poster at ESMO By Investing.com - Investing.com South Africa
AI-driven cancer firm to present ovarian trial at ESMO 2026 - Stock Titan
Compugen to Present Phase 1 MAIA-Ovarian Trial-in-Progress Poster at ESMO Gynaecological Cancers Congress 2026 - Yahoo Finance
Compugen Ltd Stock (CGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):